OVID - NASDAQ
Ovid Therapeutics Inc.
$2.48
+3.3%Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
At a Glance
Live SnapshotOvid Therapeutics Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Ovid Therapeutics Inc. Income Statement
OVID • NASDAQ
| Ovid Therapeutics Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||
7.3M | 566K | 392K | 1.5M | 208.4M | 12.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||
(300K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (255K) | (141.7K) | (80.3K) | (0.0) | (11.8K) | (0.0) | |
7M | 566K | 392K | 1.5M | 208.4M | 12.6M | -255K | -142K | -80.3K | -56.5K | -11.8K | 0.0 | |
OPERATING INCOME | ||||||||||||
(49.4M) | (62.5M) | (59.7M) | (57.1M) | (84.2M) | (94M) | (61.4M) | (52.9M) | (65M) | (22.5M) | (13.2M) | (446.9K) | |
(24.1M) | (25.7M) | (29.6M) | (32.4M) | (37.2M) | (30.6M) | (19.3M) | (19.1M) | (15M) | (13M) | (6.6M) | (341.5K) | |
(25.6M) | (36.8M) | (28.6M) | (24.6M) | (46.9M) | (64.1M) | (42.2M) | (33.8M) | (50M) | (9.6M) | (6.6M) | (105.4K) | |
-42.4M | -61.9M | -59.3M | -55.5M | 124.2M | -81.4M | -61.4M | -52.9M | -65M | -22.5M | -13.2M | -447K | |
PRE-TAX INCOME | ||||||||||||
0.0 | 3.9M | 4.9M | 0.0 | 0.0 | 395.4K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-300K | (1K) | (1.5M) | (510.0) | (1.1K) | -700K | -1K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
25M | 35.5M | 6.9M | 1.4M | -45.7K | 395.4K | 948.2K | 952.1K | 201.5K | 120.8K | 30.3K | 0.0 | |
-17.4M | -26.4M | -52.3M | -54.2M | 124.2M | -81M | -60.5M | -52M | -64.8M | -22.4M | -13.2M | -447K | |
NET INCOME | ||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (1.3M) | (0.0) | -1.2M | (0.0) | -80.3K | -950.0 | (0.0) | (0.0) | |
-17.4M | -26.4M | -52.3M | -54.2M | 122.8M | -81M | -60.5M | -52M | -64.8M | -22.4M | -13.2M | -447K |
SEC Filings
OVID - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | May 29, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 27, 2026 | December 31, 2025 | 2025 | |
S-3 S-3 N/A | April 21, 2026 | April 21, 2026 | ||
8-K 8-K 2026 N/A | April 20, 2026 | April 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 18, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 18, 2026 | March 17, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 18, 2025 | 2025 | |
S-3 S-3 N/A | December 15, 2025 | December 15, 2025 |
Related Guides
Continue your OVID research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.